1306TiPILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. (23rd October 2018) - Ascierto, P A; Arenberger, P; Atkinson, V G; Hansson, J; Kapiteijn, E; Loquai, C; Negrier, S; Shaw, H M; Tarhini, A; Walker, J; Geib, J; Rahimian, S; et al.